URGN
UroGen Pharma Ltd.
Key Financials
Operating Income
$-124863000
↓ 29.0%
Gross Profit
$97.3M
↑ 19.4%
Revenue
$109.8M
↑ 21.4%
Net Income
$-153494000
↓ 21.0%
Total Liabilities
$305.9M
↑ 3.9%
Total Assets
$200.5M
↓ 29.8%
Cash & Equivalents
$110.7M
↓ 35.6%
Long-term Debt
$125.0M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 8-K | 6/23/2026 | View on SEC |
| 144 | 6/22/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | URGN |
| Company Name | UroGen Pharma Ltd. |
| CIK | 1668243 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | L3 |
| Phone | 972 9 770 7601 |